The Consortium established the Immune Assay Proficiency Panel Program to help facilitate and harmonize immune monitoring approaches in the cancer immunotherapy field aimed at minimizing variability and promoting transparency and reproducibility in immune assay monitoring data, data interpretation, and data reporting.
The Proficiency Panel Program sought to:
Define criteria for and support harmonization and validation of the assay for laboratories
Determine the value of resulting criteria in the cancer immunotherapy community
Offer training programs to enhance assay performance and comparability between laboratories
Establish immune assays as standard monitoring tools
To date, the CIC has completed panels for Elispot, peptidemultimer assays, intracellular cytokine staining, and Luminex, and has published harmonization guidelines for Elispot and HLA-peptide multimer assays.